CAFC Finds ANDA Infringement Despite Differences Between FDA Labeling And Claim Language

by Foley & Lardner LLP
Contact

In a non-precedential decision issued in Braintree Labs., Inc. v. Breckenridge Pharmaceutical, Inc., the Federal Circuit reversed the district court’s grant of summary judgment of noninfringement in favor of Breckenridge, and remanded for entry of judgment in favor of Braintree. In reaching its decision, the court held Breckenridge to its previous stipulations, and found that proposed ANDA labeling for “colon cleansing” induced infringement of claims directed to “inducing purgation.”

The Patent At Issue

The patent at issue was Braintree’s U.S. Patent 6,946,149, which is listed in the Orange Book for its SUPREP® Bowel Prep Kit for preparing patients for colonoscopies. Reexamined claim 15 was treated as representative (emphasis added to terms at issue):

  1. A composition for inducing purgation of the colon of a patient, the composition comprising from about 100 mL to about 500 mL of an aqueous hypertonic solution comprising an effective amount of Na2SO4, an effective amount of MgSO4, and an effective amount of K2SO4, wherein the composition does not produce any clinically significant electrolyte shifts and does not include phosphate.

The district court granted Breckenridge’s motion for summary judgment of noninfringement because its product “is administered as 946 ml of aqueous solution, and thus falls outside the recited volume range.” In reaching this decision, the court construed the volume limitation as “the entire volume of solution administered to a patient over a treatment period rather than the volume of a single bottle, or half-dose.” The district court also found “that Breckenridge’s ANDA label could not induce infringement under § 271(e)” because “inducing purgation [as claimed] without ‘achieving a fully cleansed colon’ is not an FDA-approved use of Breckenridge’s product.”

Braintree’s SUPREP® product also is administered at a volume of 946 ml, in divided doses. Thus, it seems that if Breckenridge’s ANDA does not infringe the ‘149 patent, the ‘149 patent would not cover Braintree’s product either.

The Prior Novel Litigation

The Federal Circuit previously considered the ‘149 patent in ANDA litigation between Braintree and Novel, which you can read more about in this article. In that case, the Federal Circuit upheld the district court’s claim construction, which interpreted “purgation” as “an evacuation of a copious amount of stool from the bowels after oral administration of the solution.” Although the district court had granted summary judgment of noninfringement in view of its claim construction, the Federal Circuit vacated that ruling.

In so doing, the Federal Circuit explained that one bottle of product could infringe under that claim construction even if two are required for full cleansing since the claims only recite “inducing purgation.”

Breckenridge’s Stipulations

While the Novel case was on appeal, Breckenridge stipulated to the district court’s construction of “purgation” in Novel, and “further stipulated to ‘be bound by a final decision in the Novel Case . . . on any issues having to do with patent invalidity . . . and non-infringement’ other than the ‘from about 100 ml to about 500 ml’ limitation.”

The Federal Circuit Decision in Breckenridge

The Federal Circuit decision was authored by Judge Moore and joined by Judges Newman and Wallach. As the opinion explains, the issues on appeal “center[ed] on the relationship between the ‘purgation’ and [volume] limitations,” and the extent of the preclusive effect of Novel on the construction of the volume limitation. The Federal Circuit also addressed the relevance of the differences between the proposed ANDA label and the claim language.

On the first issue, Breckenridge argued that Novel was not controlling because the volume limitation was not at issue in that case, but the Federal Circuit disagreed. The court reviewed the record in Novel, and found that “[t]he meaning of the [volume] term … was necessarily connected to our construction of ‘purgation,” and that “Novel intertwined the volume and purgation limitations throughout its briefing.” The court explained:

In Novel, this court construed “from about 100 ml to about 500 ml” to be the amount of the composition that induces “purgation,” which is less than full cleansing.

The Federal Circuit emphasized that it was Breckenridge’s own stipulations that bound it to “a claim construction decision in which it was neither a party nor in privity with one.”

On the second issue, Breckenridge argued that its ANDA labeling did not induce infringement of the claims, because “colon cleansing” is different from “inducing purgation” of the colon. The Federal Circuit disagreed with the district court’s finding that “inducing purgation” is a distinct use rather than “a mechanism to achieve the goal of full colon cleansing.” The Federal Circuit distinguished the facts at hand from other cases finding that proposed ANDA labels would not induce infringement where the indicated use was different from the claimed use.

[I]nducing purgation is not a distinct use of Breckenridge’s proposed product; inducing purgation is the means by which the approved indication achieves its result. …. Breckenridge concedes that its proposed product “cleanses the colon of a patient by inducing purgation” when taken as directed by its label.

The Federal Circuit continued:

We hold that Breckenridge’s labeled indication for colon cleansing “recommends or suggests to physicians that the drug is safe and effective for administration to patients for the purposes of inducing [purgation].” …. Because Breckenridge’s ANDA label “instruct[s] how to engage in an infringing use, [it] show[s] an affirmative intent that the product be used to infringe.”

In view of these findings and other stipulations Breckenridge had made, the Federal Circuit reversed the district court’s grant of summary judgment and remanded with an instruction to enter judgment for Braintree.

Differences Between Label Language And Claim Language

This decision shows that differences between proposed ANDA labeling and claim language will not always lead to a finding of noninfringement. In its decision, the Federal Circuit distinguished a number of cases where such differences did preclude liability for inducing infringement, but drew a line here. Although this decision is non-precedential, the court’s discussion of purgation as the “mechanism” by which colon cleansing is achieved may be of interest to patents that claim the underlying mechanism of action by which an active agent exerts its therapeutic effect.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley & Lardner LLP | Attorney Advertising

Written by:

Foley & Lardner LLP
Contact
more
less

Foley & Lardner LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.